<?xml version="1.0" encoding="UTF-8"?>
<p>The results of the current study suggest that 
 <bold>TPBIA </bold>crosses the blood-brain barrier, possesses neuroleptic activity and exerts antioxidative activity. The above constitute preliminary 
 <italic>in vivo/vitro </italic>evidence suggesting that 
 <bold>TPBIA </bold>could merit further investigation as a potential candidate as an antipsychotic agent with novel and clinically important properties.
</p>
